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25 mice/group; P < 0.001). Speciﬁc GrB inhibition by iNKT
pre-treatment with the non-competitive inhibitor Z-AAD-
CMK abrogated CD2/CD3/CD28 augmented iNKT cytotox-
icity, both in vitro and in vivo. Using permutations of CD2,
CD3, and CD28 stimulation combined with speciﬁc inhibitors
of the PI3K-AKT-mTORC pathway, we deﬁned that CD3/
CD28-co-stimulated, PI3K-downstream, mTORC2-driven
AKT activation directly up-regulates GrB protein expression
and augments GrB-dependent cytotoxicity in expanded hu-
man iNKT cells. Notably, CD2/CD3/CD28-induced augmented
iNKT killing was not inhibited by cyclosporin A, rapamycin,
or tacrolimus. These data demonstrate the novel potential for
augmentation of cytokine secretion and cytotoxicity in hu-
man iNKT cells through AKT signaling independent of
mTORC1 or NF-AT, deﬁning a key pathway for control of iNKT
effector functions with broad implications for immuno-
therapy, vaccine augmentation, and anti-infective therapies.
As our studies utilized random donor human iNKT cells
expanded using a clinically applicable protocol, these data
are directly relevant to therapeutic human iNKT cell
manipulation to separate GVHD and GVT in the peri-
transplant or non-transplant setting of human iNKT
immunotherapy.503
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Allogeneic hematopoietic cell transplantation (allo-HCT) for
hemoglobinopathies is restricted by limited matched donors
and by graft rejection and graft-versus-host disease (GVHD)
after alternative donor HCT. Based upon our clinical data in
aplastic anemia (Pillai et al, ASBMT 2011), we pre-clinically
assessed non-myeloablative Total Lymphoid Irradiation (TLI)
+ Anti-Thymocyte Serum (ATS) +/- cyclophosphamide (CTX)
vs. total body irradiation (TBI)/ATS +/- CTX in an MHC-mis-
matched BALB/c (H-2d) into HW-80 (H-2b) b-thalassemia
(HW-80 b-thal+/-) model.
Methods: Wild-type (WT) and b-thal+/- HW-80 mice
received TLI (240 cGy x 10) + ATS (TLI/ATS, n ¼ 10), +/- CTX
(200 mg/kg) (TLI/ATS/CTX, n ¼ 15), ATS/CTX alone (n ¼ 10),
or ATS/CTX with 1200 cGy, 600 cGy, or 300 cGy TBI (1200 T/
A/C, 600 T/A/C, 300 T/A/C; n ¼ 10 each), and 50 x 106 bone
marrow + 60 x 106 splenocytes (BMT) from WT BALB/c do-
nors. Survival, weekly weight, day 28 and day 100 tri-lineage
engraftment and CBC, and histopathologic GVHD were
assessed.
Results: WT HW-80 recipients of either TLI/ATS or TLI/ATS/
CTX engrafted through day 100; HW-80 b-thal+/- mice had >
40% graft rejection after TLI/ATS + BMT, but 100% graft
retention after TLI/ATS/CTX + BMT, indicating a disease-
associated engraftment barrier overcome by addition of CTX
to TLI/ATS. All engrafting b-thal+/- mice showed stable mixed
hematopoietic chimerism and day 100 hematocrit (Hct)
correction (P ¼ 0.01 vs untreated b-thal+/-). However, TLI/
ATS/CTX recipients had no GVHD, whereas engrafting TLI/
ATS mice developed lethal GVHD by day 100 [cumulative
scores: TLI/ATS/CTX: 0.3 +/- 0.2; TLI/ATS: 6.8 +/- 0.9; P <
0.01]. 100% of 1200 T/A/C, 60% of 600 T/A/C, and 40% of 300 T/A/C mice engrafted. In all T/A/C groups, > 80% engrafters had
lethal GVHD, whereas > 70% of 100-day survivors showed
non-engraftment. We delineated that recipient regulatory
MDSC induce tolerance via MHC-independent in vivo
expansion of donor Foxp3+ nTreg after TLI/ATS + BMT (van
der Merwe et al, J Immunol 2013). We found signiﬁcant (P <
0.001) increase in recipient CD11b+Gr-1(G)hi MDSC in TLI/
ATS/CTX- versus TLI/ATS-conditioned b-thal+/- mice, with
increased number (P < 0.01) and proliferation (P < 0.05) of
donor Foxp3+ nTreg and decreased CD8+ T cell number and
proliferation (P < 0.01) in spleens at day 6. In adoptive
transfers, TLI/ATS/CTX-derived recipient CD11b+Gr-1Ghi
MDSC regulated otherwise lethal GVHD through day 100
post-BMT in 1200 cGy TBI-conditioned WT B6 recipients of
WT BALB/c BMT. Our data indicate that TLI/ATS/CTX facili-
tates robust recipient <–> donor tolerance, provide pre-
clinical support for application of TLI/ATS/CTX prior to
(potentially MHC-mismatched/haploidentical) allo-HCT for
hemoglobinopathies, and give the ﬁrst direct evidence for an
innate immune mechanism of alkylator-associated trans-
plantation tolerance, which we propose to validate in the
context of a clinical trial.504
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Introduction: While DCBT has been associated with high
PFS in both children & adults, rates of grade II-IV aGVHD are
signiﬁcant in patients transplanted with calcineurin inhibi-
tor/ mycophenolate mofetil (CNI/MMF) immunosuppression
(IS) without anti-thymocyte globulin. However, GVHD
biology in DCBT recipients appears distinct from that of adult
donor allografts with a high incidence of corticosteroid
responsiveness & low rates of chronic GVHD. Consequently,
the impact of aGVHD upon long-term PFS in DCBT may be
different to that of adult donor allografts & is not established.
Methods: We analyzed the time to systemic (sys.) IS cessa-
tion, transplant-related mortality (TRM), relapse, & PFS in a
day 100 landmark analysis of DCBT recipients transplanted
for hematologic malignancies who were engrafted &
progression-free according to the incidence & severity of
their aGVHD by day 100.
Results: 129 day 100 progression-free DCBT survivors (me-
dian age 36 years, range 0.9-70) were evaluated. Of this
cohort, 80 (62%) had grade II-IV aGVHD (55 grade II, 21 grade
III, & 4 grade IV disease), & all 129 patients were on sys.IS at
day 100.With a median follow-up of 4.8 years (range 1.2-9.0)
in this cohort, the cumulative incidence of achieving sus-
tained sys.IS cessation was 33% (95%CI: 25-42) at 1-year, 55%
(95%CI: 45-63) at 2-years, & 61% (95%CI: 51-69) at 3-years
